Laurence Rulleau
President bij Find Therapeutics
Profiel
Laurence Rulleau is currently a Director at DalCor Pharmaceuticals Canada, Inc., PreciThera, Inc., adMare Bioinnovations, and Find Therapeutics.
Additionally, Dr. Rulleau is the President & Director at Find Therapeutics.
Prior to these current positions, Dr. Rulleau was a Managing Partner at CTI Capital, Inc. Dr. Rulleau has also held positions as a Director at Neomed Institute and as an Analyst at Blackmont Capital Securities.
Dr. Rulleau holds a doctorate degree from the University of Montréal and a graduate degree from Université du Québec à Montréal.
Actieve functies van Laurence Rulleau
Bedrijven | Functie | Begin |
---|---|---|
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | Directeur/Bestuurslid | - |
adMare Bioinnovations
adMare Bioinnovations adMare Bioinnovations engages in the provision of research for its academic and biotech partners. The company was founded in 2011 and is headquartered in Vancouver, Canada. | Directeur/Bestuurslid | - |
CTI Capital, Inc.
CTI Capital, Inc. Investment ManagersFinance CTI Capital, Inc. is a Venture Capital firm, a subsidiary of CTI Capital Groupe, Inc. founded in 1987. CTI Capital, Inc. is headquartered in Montréal. | Private Equity Investor | 01-11-2014 |
Find Therapeutics
Find Therapeutics BiotechnologyHealth Technology Find Therapeutics develops therapeutics for inflammatory and fibrotic disease. The company is headquartered in Saint-Laurent, Canada. | President | - |
PreciThera, Inc.
PreciThera, Inc. Pharmaceuticals: MajorHealth Technology Precithera, Inc. engages in drug development business. The firm focuses on the design and the development of biological agents for the treatment of orphan diseases. The company was founded by Philippe Crine and Susan Schiavi on May 26, 2016 and is headquartered in Outremont, Canada. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Laurence Rulleau
Bedrijven | Functie | Einde |
---|---|---|
Blackmont Capital Securities
Blackmont Capital Securities Investment Banks/BrokersFinance Blackmont Capital Securities is the broker subsidiary of Blackmont Capital, Inc. They focus on sectors such as energy, metals and minerals, biotechnology and health services, technology and special situations, business trusts and industrials, consumer staples, real estate and hospitality and financial services. Blackmont screens for emerging influences, shifts in market dynamics and changes in corporate fundamentals to identify immediate growth opportunities with the best risk-reward profile | Analyst-Equity | 02-10-2007 |
Neomed Institute
Neomed Institute Pharmaceuticals: OtherHealth Technology Neomed Institute operated as a non-profit organization for pharmaceutical companies. It offered analytical services, drug development, licensing, and drug discovery. The company was founded in 2012 and was headquartered in Montreal, Canada. | Directeur/Bestuurslid | - |
Opleiding van Laurence Rulleau
University of Montréal | Doctorate Degree |
Université du Québec à Montréal | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 7 |
---|---|
Blackmont Capital Securities
Blackmont Capital Securities Investment Banks/BrokersFinance Blackmont Capital Securities is the broker subsidiary of Blackmont Capital, Inc. They focus on sectors such as energy, metals and minerals, biotechnology and health services, technology and special situations, business trusts and industrials, consumer staples, real estate and hospitality and financial services. Blackmont screens for emerging influences, shifts in market dynamics and changes in corporate fundamentals to identify immediate growth opportunities with the best risk-reward profile | Finance |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada. | Health Technology |
Neomed Institute
Neomed Institute Pharmaceuticals: OtherHealth Technology Neomed Institute operated as a non-profit organization for pharmaceutical companies. It offered analytical services, drug development, licensing, and drug discovery. The company was founded in 2012 and was headquartered in Montreal, Canada. | Health Technology |
adMare Bioinnovations
adMare Bioinnovations adMare Bioinnovations engages in the provision of research for its academic and biotech partners. The company was founded in 2011 and is headquartered in Vancouver, Canada. | |
CTI Capital, Inc.
CTI Capital, Inc. Investment ManagersFinance CTI Capital, Inc. is a Venture Capital firm, a subsidiary of CTI Capital Groupe, Inc. founded in 1987. CTI Capital, Inc. is headquartered in Montréal. | Finance |
Find Therapeutics
Find Therapeutics BiotechnologyHealth Technology Find Therapeutics develops therapeutics for inflammatory and fibrotic disease. The company is headquartered in Saint-Laurent, Canada. | Health Technology |
PreciThera, Inc.
PreciThera, Inc. Pharmaceuticals: MajorHealth Technology Precithera, Inc. engages in drug development business. The firm focuses on the design and the development of biological agents for the treatment of orphan diseases. The company was founded by Philippe Crine and Susan Schiavi on May 26, 2016 and is headquartered in Outremont, Canada. | Health Technology |